Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: William D. Tap, Hans Gelderblom, Silvia Stacchiotti, Emanuela Palmerini, Stefano Ferrari, Jayesh Desai, Sebastian Bauer, Jean-Yves Blay, Thierry Alcindor, Kristen N. Ganjoo, Javier Martin Broto, Christopher W. Ryan, Dale Edward Shuster, Ling Zhang, Qiang Wang, Henry Hsu, Paul S. Lin, Sandra Tong, Andrew J. Wagner
Institutions: Memorial Sloan Kettering Cancer Center, Leiden University Medical Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Istituto Ortopedico Rizzoli, The Royal Melbourne Hospital, Peter MacCallum Cancer Centre, Essen University Hospital, Centre Léon Bérard, McGill University Health Centre, Stanford Cancer Institute, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Oregon Health & Science University, OHSU Knight Cancer Institute, Daiichi Sankyo (United States), Plexxikon (United States), Dana-Farber Cancer Institute
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891329037